Europe Diet Pills Market

Market Outlook for Europe Diet Pills

Newly released data in Fact.MR’s market analysis shows that demand for diet pills in Europe is expected to increase at a CAGR of 2.6% through 2031, with the market being valued at US$ 669 Mn currently.

Sales of glucomannan drugs are expected to grow from US$ 258.1 Mn in 2020 to around US$ 361.2 Mn by 2031, while those of herbal supplements from US$ 455.1 Mn to around US$ 611.6 Mn.

Detailed Insights Offered in Europe Diet Pills Industry Survey:

• Market Estimates and Forecasts (2016-2031)
• Key Drivers and Restraints Shaping Market Growth
• Segment-wise, Country-wise, and Region-wise Analysis
• Competition Mapping and Benchmarking
• Key Product Innovations and Regulatory Climate
• COVID-19 Impact on Sales of Diet Pills in 2020 and Beyond and How to Navigate
• Recommendation on Key Winning Strategies

Sales Analysis of Diet Pills in Europe from 2016 to 2020 Vs Market Outlook for 2021 to 2031

Market growth in terms of CAGR from 2016 to 2020 for diet pills in Europe has been observed a 0.7%, wherein, glucomannan had the highest market share of 39.5%in 2020.

More number of customers are inclining towards dietary supplements such as diet pills in their daily dietary habits. Moreover, customers across the U.K. and Germany, where cases of obesity are rising at a fast pace, are adopting preventive measures and focusing on the consumption of dietary supplements.

Increasing health awareness among customers and rising willingness to spend on dietary supplements and nutrition are driving demand for diet pills as an appetite suppressant across the continent. Additionally, development of distribution channels for diet pills is leading to better accessibility, which is also expected to boost market growth.

In addition, growing geriatric population and rising healthcare costs throughout Europe are anticipated to support the market in gaining significant traction over the coming years.

Considering these statistics and shift in dynamics for demand for diet pills as a fat blocker, over the forecast period of 2021-2031, the market is expected to expand at around 2.6% CAGR.

What are the Key Opportunities Ahead for European Diet Pill Manufacturers?

Opportunity for key players for increased sales of fat blocker diet pills exists with rising awareness. Manufacturers involved in the development of diet pills are focusing on the development of highly advanced medicines that can satisfy end users. Most studies reveal that people who want to look and feel healthier seek more options in addition to just diet and exercise.

Increasing prevalence of cardiovascular diseases, rising cholesterol levels, and surging lifestyle diseases are also some of the key factors that are contributing to the increase in the number of consumers looking for weight loss supplements, thereby complementing the sales of diet pills for appetite control.

What is the Main Restraining Factor for Diet Pill Suppliers in Europe?

Higher cost involved in drug development of prescription obesity drugs is a great challenge for manufacturers of diet pills. Moreover, prolonged time required for drug development activities and also need for intensive clinical trials to test drugs add to the expenditure.

Thus, manufacturers of metabolism raising diet pills must stay cautious and ensure investments in markets that can provide better return on investments. Restrictions posed by higher R&D of obesity drugs will hinder market growth to some extent.

Limited availability of approved drugs has resulted in large-scale adoption of off-label drugs, which means, prescribed class of drugs are effective in the treatment of obesity but not approved by regulatory authorities as an actual drug to treat the condition. Thus, widespread adoption of off-label drugs limits the penetration of actual drugs, subsequently restraining market.

How is Increasing Prevalence of Obesity and Associated Comorbidities Impacting Demand for Diet Pills for Appetite Suppression?

Growing incidence of obesity is a major challenge to disease prevention across the globe. It is estimated that obesity is a major public health problem in Europe. For instance, in 2016, according to Eurostat data, obesity affects 10%-30% of adults, and overweight affects 30%-70% adults in European Union countries.

Weight loss with both, prescription-based diet pills and over-the-counter diet pills play a vital role in the treatment of highly critical obesity and diseases associated with it, such as diabetes, hypertension, and sleep apnea.

Cases of obesity among adolescents and children aged 5-19 have grown dramatically from just 4% in 1975 to over 18% in 2016. This shows that prevalence of obesity has nearly tripled between 1975 and 2016.

Thus, rising incidence of obesity and related medical conditions will lead to growing adoption of drugs for weight loss and obesity, which will accelerate demand for weight loss pills.

Country-wise Analysis

Why is Demand for Diet Pills Surging across the U.K.?

According to projections by Fact.MR, the market in the U.K. is expected to observe lucrative growth of over the forecast period with a value of approx. US$ 193 Mn by 2031.

In the U.K., around 29% of adults were categorized as obese by the World Health Organization (WHO) in 2017, growing from 26% in 2016. Owing to this, people in the country have increased the consumption of dietary supplements.

Customers here have better access to knowledge about nutrition and health, owing to social media, lifestyle blogs, and active media telecasts. In addition, key players are increasing investments in new product development and advertising, which, consequently, boosts demand for diet pills in the country.

Furthermore, e-Commerce platforms aid market growth at an incredible rate due to the ability to access different brands and for the convenience that it provides.

What Allows Germany to Lead the Diet Suppressants Market in Western Europe?

Sales of diet suppressants in Germany are expected to experience lucrative growth and progress at a CAGR of around 3%. Major factor driving this market is rising concerns about health and increasing deficiency levels in the country.

The German market for diet pills is developing at a steady rate as customers have become more aware about health and are ready to spend on products that are observed as advantageous. Particularly, customers who don’t follow a balanced diet are choosing dietary supplements to the prevent deficiency of essential nutrients.

Also, the trend of self-medication is increasing in Germany due to rising awareness about nutrition deficiency-related disorders and over-the-counter products.

Category-wise Insights

Which Drug Class of Diet Pills Witnesses High Demand in Europe?

Glucomannan accounted for the largest market share of 39.5% in 2020, owing to its effectiveness for appetite suppression.

Glucomannan is a water-soluble, natural dietary fiber extracted from elephant yam roots, called konjac. It absorbs a lot of liquid; a little amount of glucomannan poured to a glass of water turns the total contents into a gel.

These exceptional properties are believed to popularize its use for weight loss. It is different from other soluble fibers, because it is extremely viscous, making it specifically effective for weight loss.

Why is Demand for Herbal Supplements High across Europe?

Herbal diet pills (supplements) represented the largest market share and accounted for a revenue of US$ 444.3 Mn in 2020, prompted by increase in use of organically obtained products.

Herbal supplements are natural supplements added to a diet for enhancing cardiovascular health, immunity, digestion, etc. These products are protective in nature and help prevention of disease rather than concentrating on the cure.

Other dietary supplements include minerals and vitamins (such as multivitamin or a vitamin C). In contrast, herbal supplements are extracted from botanicals (plant and herbs products) and substances that are obtained from a natural source.

How Has COVID-19 Impacted Sales of Diet Pills in the European Market?

In January 2020, the World Health Organization (WHO) declared COVID-19 pandemic as a world health emergency. The pandemic emergency is challenging governments to execute monetary measures and fiscal policies that sustain economic activity and support credit markets.

Because of the COVID-19 pandemic, the diet pills industry in Europe improved among various pockets as maximum of European customers increased their interest on overall wellness and health.

For example, the outbreak of COVID-19 in March 2020 in Poland had a remarkable effect on buying patterns that transformed into volume of product sales. From February to March, the largest sales rise was recorded for products from the health industry, such as OTC drugs, thereby benefiting the dietary supplements market.

Competitive Landscape

Key players are focusing on expansion in emerging countries and introducing features in their product lines. Various manufacturers are spending on developing integrated software that can include cutting-edge technologies to understand the formulation of diet pills.

Market players are also engaged in expanding their regional presence through acquisitions, collaborations, expansions, product launches, and improvement of distribution channels.

• In September 2019, Currax™ Pharmaceuticals LLC announced the acquisition of Nalpropion Pharmaceuticals, Inc. Currax now owns the worldwide rights to CONTRAVE, which is the number one prescribed weight-loss brand medication.
• In June 2020, Holland & Barrett and Deliveroo announced a new partnership to deliver a selected range of more than 200 products from 50 stores across the U.K.
• In September 2018, Nature's Way Products, LLC and Natural Products Canada entered into a new investment agreement for investing in new companies working in natural products sectors such as supplements and dietary ingredients.

Europe Diet Pills Market Report Scope

Report Attribute	Details
Forecast Period	2021-2031
Historical Data Available for	2016-2020
Market Analysis	USD Million for Value Volume (Units) Pricing Analysis
Key Regions Covered	Europe
Key Countries Covered	Germany U.K. France Italy Spain Benelux Russia
Key Market Segments Covered	Drug Class Drug Type Mechanism Distribution Channel
Key Companies Profiled	GlaxoSmithKline plc. Cheplapharm Arzneimittel GmbH Holland & Barrett Retail Limited Cresent Pharma. Currax Pharmaceuticals LLC (OREXIGEN THERAPEUTICS IRELAND LTD) Himalaya Wellness (The Himalaya Drug Company) Nature's Way Products, LLC zeinpharma SimplySupplements Lindens Health + Nutrition
Report Coverage	Market Forecasts Company Share Analysis Competition Intelligence DROT Analysis Market Dynamics Challenges Strategic Growth Initiatives
Customization & Pricing	Available upon Request

Segments Covered Europe Diet Pills Industry Research

• By Drug Class :

  • Lipase Inhibitors
  • Choline
  • Glucomannan
  • Garcinia Cambogia
  • Others

• By Drug Type :

  • Prescription Drugs
  • OTC Drugs
  • Herbal Supplements

• By Mechanism :

  • Metabolism Raising Diet Pills
  • Fat Blocking Diet Pills
  • Appetite Controlling Diet Pills
  • Others

• By Distribution Channel :

  • Diet Pills Sold at Hospital Pharmacies
  • Diet Pills Sold at Retail Pharmacies
  • Diet Pills Sold at Clinics
  • Online Sales of Diet Pills (e-Commerce)
    • Stores
    • Amazon
    • Pharmacies
  • Sales of Diet Pills by Drug Stores